MannKind says HFSA analyses show Furoscix ReadyFlow autoinjector matches IV furosemide urine output
Bitget2026/10/10 00:00MannKind flagged new clinical analyses on Furoscix ReadyFlow, with results presented at HFSA 2026 on Oct. 9-12. Studies indicated the autoinjector delivered diuretic effects comparable to intravenous furosemide, supporting outpatient treatment of fluid overload. Data also supported flexible injection-site use without loss of performance, easing real-world administration. Cross-study findings suggested similar responses versus the older Furoscix on-body infusor, supporting a transition to the newer device. The update follows FDA clearance in July 2026 and a U.S. launch positioning ReadyFlow as an IV-equivalent, rapid-delivery option. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610092000PRIMZONEFULLFEED9841965) on October 10, 2026, and is solely responsible for the information contained therein.
- MannKind flagged new clinical analyses on Furoscix ReadyFlow, with results presented at HFSA 2026 on Oct. 9-12.
- Studies indicated the autoinjector delivered diuretic effects comparable to intravenous furosemide, supporting outpatient treatment of fluid overload.
- Data also supported flexible injection-site use without loss of performance, easing real-world administration.
- Cross-study findings suggested similar responses versus the older Furoscix on-body infusor, supporting a transition to the newer device.
- The update follows FDA clearance in July 2026 and a U.S. launch positioning ReadyFlow as an IV-equivalent, rapid-delivery option.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
MicroStrategy Could Be Removed From Major Global Stock Indexes
Bitcoin Reserve Model Faces Major Test! MSCI’s New Rules "Target" Strategy (MSTR.US): May Be Removed from Global Indexes, Tens of Billions of Dollars in Sell-off Pressure Await
Recently, MSCI Inc. approved new rules that could ultimately result in the removal of Strategy Inc. from its global equity benchmark index. This move may trigger stock sell-offs worth several billions of dollars and add new pressure to the financing model behind Michael Saylor's massive bitcoin holdings.
Alcoa (AA.US) reported third-quarter revenue of $3.7 billion, up nearly 24% year-on-year.
Alcoa reported its financial results for the third quarter of 2026 on Thursday, showing a revenue of 3.704 billion USD for the quarter.
Crypto prices
More
